Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
2,897.00    45.00 (1.58%)
Bid:
2,892.00
Ask:
2,894.00
Spread: 2.00 (0.069%)
Market Cap: £4.04b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Completed divestment

1 Jul 2022 07:00

RNS Number : 9187Q
Croda International PLC
01 July 2022
 

Stock market announcement

1 July 2022

Completed divestment - transitioning to a pure-play Consumer Care and Life Sciences company

Croda International Plc ('Croda'), which uses smart science to create high performance ingredients and technologies that improve lives, today announces the completion of the divestment of the majority of its Performance Technologies and Industrial Chemicals businesses to a wholly owned subsidiary of Cargill Inc ('Cargill'), as more fully described in Croda's initial announcement on 22 December 2021.

The gross proceeds will be approximately €775m (approximately £667m), subject to small, customary adjustments for cash and debt-like instruments, and working capital, in line with the earlier announcement. The divestment and the associated proceeds exclude Croda Sipo ('Sipo'), a Chinese joint venture in which Croda has a 65% shareholding. Croda continues to discuss with its joint venture partner the acquisition of its stake in Sipo, to enable a subsequent sale by Croda to Cargill of 100% of Sipo for €140m. 

Steve Foots, Chief Executive of Croda, said: "This divestment accelerates Croda's transition to being a pure-play Consumer Care and Life Sciences company. We will redeploy capital and resources to scale our consumer, health and crop care technologies, helping to deliver consistent, superior sales growth and even stronger profit margins."

 

Further information

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

 

Advisers to Croda

 

Morgan Stanley & Co. International Plc (Financial Adviser & Corporate Broker)

Shirav Patel, Andrew Foster

Centerview Partners (Financial Adviser)

James Hartop

Freshfields Bruckhaus Deringer (Legal Adviser)

Oliver Lazenby

Teneo (Financial PR)

Charlie Armitstead

 

Disclaimers

 

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority and the PRA in the UK is acting exclusively as financial adviser and corporate broker to Croda and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

 

Centerview Partners UK LLP ("Centerview Partners") is authorised and regulated by the Financial Conduct Authority. Centerview Partners is acting exclusively for Croda and no one else in connection with the matters referred to in this announcement. Centerview Partners is not and will not be responsible to anyone other than Croda for providing the protections afforded to its clients or for providing advice in connection with the contents of this announcement or any other matter referred to in this announcement. Neither Centerview Partners, nor any of its affiliates, owes or accepts any duty, liability or responsibility whatsoever to any person who is not a client of Centerview Partners in connection with this announcement, any statement contained herein or otherwise.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISFMMRTMTIJBIT
Date   Source Headline
13th Mar 202011:58 amRNSDirector/PDMR Shareholding
13th Mar 202011:57 amRNSDirector/PDMR Shareholding
13th Mar 202011:57 amRNSDirector/PDMR Shareholding
13th Mar 202011:56 amRNSDirector/PDMR Shareholding
11th Mar 20202:13 pmRNSDirector/PDMR Shareholding
10th Mar 20204:11 pmRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSResults for the year ended 31 December 2019
12th Feb 20203:47 pmRNSHolding(s) in Company
11th Feb 20203:14 pmRNSDirector/PDMR Shareholding
31st Jan 20204:22 pmRNSHolding(s) in Company
30th Jan 20202:36 pmRNSHolding(s) in Company
14th Jan 20203:42 pmRNSHolding(s) in Company
13th Jan 20204:12 pmRNSDirector/PDMR Shareholding
30th Dec 201911:45 amRNSDirector/PDMR Shareholding
20th Dec 20194:00 pmRNSHolding(s) in Company
17th Dec 20194:52 pmRNSHolding(s) in Company
16th Dec 20197:00 amRNSDirectorate Change
12th Dec 201910:40 amRNSDirector/PDMR Shareholding
9th Dec 20193:21 pmRNSHolding(s) in Company
4th Dec 20195:11 pmRNSHolding(s) in Company
27th Nov 20195:13 pmRNSHolding(s) in Company
25th Nov 20193:47 pmRNSHolding(s) in Company
22nd Nov 201910:17 amRNSDirector/PDMR Shareholding
12th Nov 20195:41 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
7th Nov 20196:04 pmRNSHolding(s) in Company
7th Nov 201910:04 amRNSHolding(s) in Company
1st Nov 20194:45 pmRNSDirector/PDMR Shareholding
15th Oct 20194:54 pmRNSTransaction in Own Shares
11th Oct 20195:40 pmRNSDirector/PDMR Shareholding
7th Oct 20197:00 amRNSCroda investor seminar focusing on Life Sciences
3rd Oct 20194:20 pmRNSDirector/PDMR Shareholding
13th Sep 20192:27 pmRNSDirector/PDMR Shareholding
11th Sep 20193:00 pmRNSDirector/PDMR Shareholding
11th Sep 20192:28 pmRNSHolding(s) in Company
13th Aug 20194:12 pmRNSDirector/PDMR Shareholding
25th Jul 20193:35 pmRNSDirector/PDMR Shareholding
24th Jul 20197:00 amRNSResults for the six months ended 30 June 2019
11th Jul 20193:11 pmRNSDirector/PDMR Shareholding
14th Jun 20193:01 pmRNSDirector/PDMR Shareholding
4th Jun 20193:24 pmRNSDirector/PDMR Shareholding
13th May 20193:20 pmRNSDirector/PDMR Shareholding
3rd May 20192:59 pmRNSDirector/PDMR Shareholding
1st May 20194:32 pmRNSDirector/PDMR Shareholding
29th Apr 20198:54 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.